The proteomic response in glioblastoma in young patients

Journal of Neuro-Oncology

Volumn 119, Issue 1, 2014, Pages 79-89

  Deighton, Ruth F ^a,b   Le Bihan, Thierry ^b   Martin, Sarah F ^b   Barrios Llerena, Martin E ^b   Gerth, Alice M J ^b   Kerr, Lorraine E ^b   McCulloch, James ^b   Whittle, Ian R ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Clinical proteomics; Glioblastoma; Patient age

Indexed keywords

ACOT7 PROTEIN; ALDOA PROTEIN; APOA1 PROTEIN; ATP6V1B2 PROTEIN; ATP6V1E1 PROTEIN; CELL PROTEIN; CHAPERONIN 60; CKB PROTEIN; CKMT1A PROTEIN; CLIC4 PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; DERMCIDIN; GFAP PROTEIN; GLUD1 PROTEIN; GNB1 PROTEIN; HSPA5 PROTEIN; IDH3A PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INA PROTEIN; MBP PROTEIN; NDUFS3 PROTEIN; OXCT1 PROTEIN; PEBP1 PROTEIN; PEROXIREDOXIN 3; PGAM1 PROTEIN; SNAP PROTEIN; TUBB2A PROTEIN; UCHL1 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE DEPENDENT ANION CHANNEL 2;

ADULT; AGE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MITOCHONDRION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; BRAIN TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGE FACTORS; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; MASS SPECTROMETRY; MIDDLE AGED; MITOCHONDRIA; PROGNOSIS; PROTEOMICS; SURVIVAL RATE;

EID: 84906939415     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1474-6     Document Type: Article

References (42)

1. Anderson E, Grant R, Lewis SC, Whittle IR (2008) Randomized phase III controlled trials of therapy in malignant glioma: Where are we after 40 years? Brit J Neurosurg 22:339-349 (Pubitemid 351878617)
2. Davis FG, Freels S, Grutsch J, Barlas S, Brem S (1998) Survival rates in patients with primary malignant brain tumours stratified by patient age and tumor histological type: an analysis based in surveillance, epidemiology, and end results (SEER) data, 1973-1991. J Neurosurg 88:1-10
3. Preusser M, de Ribaupierre S, Wöhrer A, Erridge SC, Hegi M, Weller M, Stupp R (2011) Current concepts and management of glioblastoma. Ann Neurol 70:9-21
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
5. Deighton RF, McGregor R, Kemp J, McCulloch J, Whittle IR (2010) Glioma pathophysiology: insights emerging from proteomics. Brain Path 20:691-703
6. Lubec G, Krapfenbauer K, Fountoulakis M (2003) Proteomics in brain research: potentials and limitations. Prog Neurobiol 69:193-211 (Pubitemid 36577323)
7. Persson O, Brynnel U, Levander F, Widegren B, Salford LG, Krogh M (2009) Proteomic expression analysis and comparison of protein and mRNA expression profiles in human malignant gliomas. Proteomic Clin Appl 3:83-94
8. MRC Brain Tumour Working Party (1990) Prognostic factors for high grade gliomas: development of a prognostic index. J Neurooncol 9:47
9. Kleinschmidt-DeMasters Meltesen L, McGavran L, Lillehei KO (2006) Characterisation of glioblastomas in young adults. Brain Pathol 16:273-286
10. Latif AZ, Signorini D, Gregor A, Grant R, Ironside JW, Whittle IR (1998) Application of the MRC brain tumour prognostic index to patients with malignant glioma not managed in randomised control trial. J Neurol Neurosurg Psychiatry 64:747-750 (Pubitemid 28274408)
11. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981. Lancet Oncol 9:29-38
12. Lutterback J, Bartelt S, Momm F, Becker G, Frommhold H, Ostertag C (2005) Is older age associated with a worse prognosis due to different patterns of care? Cancer 103:1234-1244
13. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Path 170:1445-1453 (Pubitemid 47339290)
14. Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, Passe S, Jenkins RB, Aldape KD (2002) Genetic aberrations defined by comparative genomic hybridization distinguish long-term typical survivors of glioblastoma. Cancer Res 62:6205-6210 (Pubitemid 35244472)
15. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, Wiestler OD, Lois DN, Fimmers R, von Deeimling A (2002) Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropath Exp Neurol 61:321-328 (Pubitemid 34266783)
16. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003 (Pubitemid 40349502)
17. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
18. Jansen M, Yip S, Louis DN (2010) Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 9:717-726
19. Joshi AD, Parsons DW, Velculescu VE, Riggins GJ (2011) Sodium ion channel mutations in glioblastoma patients correlate with shorter survival. Mol Cancer 10:17
20. Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H et al. (2014) for the German Glioma Network. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. Int J Cancer March 11 epub ahead of print
21. Le Bihan T, Grima R, Martin S, Forster T, Le Bihan Y (2010) Quantitative analysis of low-abundance peptides in HeLa cell cytoplasm by targeted liquid chromatography/mass spectrometry and stable isotope dilution: emphasising the distinction between peptide detection and peptide identification. Rapid Commun Mass Spectrom 24:1093-1104
22. Cox J, Matic I, Hilger M, Nagaraj N, Selbach M, Olsen JV, MannM (2009) A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics. Nat Protoc 4:698-705
23. Deighton RF, Kerr LE, Short DM, Allerhand M, Whittle IR, McCulloch J (2010) Network generation enhances interpretation of proteomic data from induced apoptosis. Proteomics 10:1307-1315
24. Santandreu FM, Brell M, Gene AH, Guevara R, Oliver J, Couce ME, Roca P (2008) Differences in mitochondrial function and anti-oxidant systems between regions of human glioma. Cell Physiol Biochem 22:757-768
25. Jia ZF, Huang Q, Kang CS, Yang WD, Wang GX, Yu SZ, Jiang H, Pu PY (2010) Overexpression of septin 7 suppresses glioma cell growth. J Neurooncol 98:329-340
26. Darsigny M, Babeu JP, Seidman EG, Gendron FP, Levy E, Carrier J, Perreault N, Boudreau F (2010) Hepatocyte nuclear factor-4alpha promotes gut neoplasia in mice and protects against the production of reactive oxygen species. Cancer Res 70:9423-9433
27. Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schroter F, Prozorovski T, Lange N, Steffen J, Rieger M et al (2010) Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 142:613-624
28. Ruschak AM, Slassi M, Kay LE, Schimmer AD (2011) Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 103:1007-1017
29. Tanahashi N, Murakami Y, Minami Y, Shimbara N, Hendil KB, Tanaka K (2000) Hybrid proteasomes. Induction by interferon-gamma and contribution to ATP-dependent proteolysis. J Biol Chem 275:14336-14345 (Pubitemid 30339716)
30. Avril T, Vauleon E, Tanquy-Roger S, Mosser J, Quillien V (2011) Mechanisms of immunomodulation in human glioblastoma. Immunotherapy 3(4Suppl):42-44
31. Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, Kubota T, Yang WK (2011) A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci 18:1048-1054
32. Aggarwal BB (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell 6:203-208
33. Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8:33-40
34. Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5:297-309 (Pubitemid 40488635)
35. Rayet B, Gelinas C (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18:6938-6947
36. Gilmore TD (2006) Introduction to NF-kB: players, pathways, perspectives. Oncogene 25:6680-6684
37. Piaggi S, Raggi C, Corti A, Pitzalis E, Mascherpa MC, Saviozzi M, Pompella A, Casini AF (2010) Glutathione transferase omega 1-1 (GSTO1-1) plays an anti-apoptotic role in cell resistance to cisplatin toxicity. Carcinogenesis 31:804-811
38. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ (2000) Activation of the IkB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103:351-361
39. Masaki M, Ikeda A, Shiraki E, Oka S, Kawasaki T (2003) Mixed lineage kinase LZK and antioxidant protein-1 activate NF-κB synergistically. Eur J Biochem 270:76-83 (Pubitemid 36056939)
40. Takami Y, Nakagami H, Morishita R, Katsuya T, Cui TX, Ichikawa T, Saito Y, Hayashi H, Kikuchi Y, Nishikawa T et al (2007) Ubiquitin carboxyl-terminal hydrolase L1, a novel deubiquitinating enzyme in the vasculature, attenuates NF-kB activation. Arterioscler Thromb Vasc Biol 27:2184-2190 (Pubitemid 350287248)
41. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM (2001) Raf kinase inhibitor protein interacts with NF-kB-inducing kinase and TAK1 and inhibits NF-kB activation. Mol Cell Biol 21:7207-7217 (Pubitemid 32953475)
42. Zanotto-Filho A, Braganhol E, Schroder R, de Souza LH, Dalmolin RJ, Pasquali MA, Gelain DP, Battastini AM, Moreira JC (2011) NFkB inhibitors induce cell death in glioblastomas. Biochem Pharmacol 81:412-424